Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kairos Pharma, Ltd. (KAPA) since 2024 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kairos Pharma, Ltd.. Table 2 shows the detailed insider transactions. This company's CIK number is 1962011.
Total stock buying since 2024: $9,828.
Total stock sales since 2024: $0.
Total stock option exercises since 2024: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 6,700 | $9,828 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-11 | 6,700 | $9,828 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-11-25 | Murali Ramachandran (VP of Research and Development) | Buy | 200 | 1.59 | 318 |
| 2024-11-22 | Samuelson Doug (Chief Financial Officer) | Buy | 2,500 | 1.50 | 3,750 |
| 2024-11-20 | Yu John S (CEO and Chairman) | Buy | 4,000 | 1.44 | 5,760 |
Insider trading activities including stock purchases, stock sales, and option exercises of KAPA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kairos Pharma, Ltd. (symbol KAPA, CIK number 1962011) see the Securities and Exchange Commission (SEC) website.